Launch of ARPEGE, a French multidisciplinary consortium to fight antibiotic resistance through preventive, diagnostic, therapeutic and economic approaches

Antabio is seeking a Clinical Pharmacologist

Antabio Awarded EUR 0.9 million funding from the Occitanie Region to support the Preclinical Development of MEM-ANT3310, Antabio’s Novel Broad-Spectrum Combination Therapy Targeting WHO’s Priority Pathogens

Antabio Receives FDA Qualified Infectious Disease Product (QIDP) Designation for MEM-ANT3310, a Novel Broad-Spectrum Combination Therapy Targeting WHO’s Priority Pathogens

Antabio Awarded $4.4 Million from CARB-X for the Further Development of its New Treatment for Pseudomonas aeruginosa Infections in Cystic Fibrosis Patients

Antabio applauds the new mechanism for reimbursement of antibiotics set up by CMS in the US

Antabio Receives QIDP Designation from the U.S. FDA for the Development of Its Metallo Beta-Lactamase inhibitor ANT2681

Antabio’s Novel Metallo β-Lactamase Inhibitor to be presented at the ASM Microbe Conference, June 20-24, San Francisco

Marc Lemonnier appointed at the Scientific Advisory Board of JPIAMR

ANTABIO Completes € 12.5M Series A

1 2 3 4 Next

Legal Notice | © copyright 2017 – Antabio – All rights reserved | Website by KWALT DIGITAL

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok